	US 11,981,748 B2
	Methods for inhibiting angiogenesis in a subject in need thereof
Gregory A. Demopulos, Mercer Island, WA (US); Hans-Wilhelm Schwaeble, Mountsorrel (GB); Thomas Dudler, Bellevue, WA (US); and Larry Tjoelker, Kirkland, WA (US)
Assigned to Omeros Corporation, Seattle, WA (US); and University of Leicester, Leicester (GB)
Filed by Omeros Corporation, Seattle, WA (US); and University of Leicester, Leicester (GB)
Filed on Nov. 17, 2020, as Appl. No. 16/950,645.
Application 16/950,645 is a division of application No. 15/476,154, filed on Mar. 31, 2017, granted, now 10,870,708.
Claims priority of provisional application 62/315,857, filed on Mar. 31, 2016.
Prior Publication US 2021/0189009 A1, Jun. 24, 2021
Int. Cl. A61K 39/00 (2006.01); A61P 27/02 (2006.01); A61P 35/04 (2006.01); C07K 16/40 (2006.01)

CPC C07K 16/40 (2013.01) [A61P 27/02 (2018.01); A61P 35/04 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

2 Claims

1. A method for treating a mammalian subject suffering from an angiogenesis-dependent benign tumor selected from the group consisting of hemangiomas, acoustic neuromas, neurofibromas, trachomas, carcinoid tumors, and pyogenic granulomas comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis, wherein the MASP-2 inhibitory agent is a MASP-2 inhibitory monoclonal antibody, or fragment thereof is a MASP-2 monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising SEQ ID NO:67 and a light chain variable region comprising SEQ ID NO:69.